Combining BeEAM with Brentuximab Vedotin for High-Dose Therapy in CD30 Positive Lymphomas before Autologous Transplantation—A Phase I Study

The prognosis for patients with CD30+ lymphomas (Hodgkin lymphoma and various T-cell lymphomas) relapsing after autologous stem cell transplantation (ASCT) is critical. Brentuximab vedotin (BV), an ADC targeting CD30, is an obvious candidate for inclusion into high-dose chemotherapy (HDCT) regimens...

Descripción completa

Detalles Bibliográficos
Autores principales: Rausch, Christian, Bacher, Ulrike, Rabaglio, Manuela, Vorburger, Corinne, Klingenberg, Anke, Banz, Yara, Daskalakis, Michael, Pabst, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503567/
https://www.ncbi.nlm.nih.gov/pubmed/36143025
http://dx.doi.org/10.3390/jcm11185378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503567/
https://www.ncbi.nlm.nih.gov/pubmed/36143025
http://dx.doi.org/10.3390/jcm11185378

Ejemplares similares